Medicaid / Low-Income Program Market Analysis

Hematology Analyzers and Reagents Market to Reach USD 8.9 Billion by 2033 at 6.4% CAGR

U.S. Medicaid hematology testing reimbursement rates are the lowest in the commercial market, often 40–60% of Medicare CLFS rates; 340B-eligible hospital labs absorb some of this margin pressure through program discounts on reagent procurement.